IP Library Granted Patent US 7,498,358
Granted Patent B2
US 7,498,358 · App. 10/498,338 · Granted Mar 3, 2009

Human ADAM-10 inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,498,358
App. No.
10/498,338
Granted
Mar 3, 2009
Kind
B2
Abstract

The present invention provides compounds useful for inhibiting the ADAM-10 protein. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role. The invention also provides methods for making bis-aryl ether sulfonyl chlorides and ADAM-10 modulators therefrom.

Claims (358)

1. A compound of structural formula I:

or a pharmaceutically acceptable salt thereof, wherein

R 1 is selected from hydrogen, alkyl, alkanoyl, arylalkyl, and arylalkanoyl, wherein

the arylalkyl and arylalkanoyl groups are unsubstituted or substituted with 1, 2, 3, 4, or 5 R 6 groups;

R 6 at each occurrence is independently selected from halogen, hydroxy, —NO 2 , —CO 2 R 10 , —CN, alkyl, alkoxy, haloalkyl, and haloalkoxy;

R 2 is selected from hydrogen, alkyl, alkoxy, alkanoyl, arylalkyl and arylalkanoyl, wherein

the arylalkyl and arylalkanoyl groups are unsubstituted or substituted with 1, 2, 3, 4, or 5 R 6 groups;

R 3 is —Z—Q—J, wherein

Z is selected from alkyl, alkoxyalkyl, alkylthioalkyl, and alkenyl, each of which is unsubstituted or substituted with 1 or 2 groups that are independently selected from alkoxy, hydroxy, and halogen;

Q is selected from a direct bond between Z and J, —C(═O)—, aryl, heteroaryl, and heterocycloalkyl, wherein

the aryl, heteroaryl, or heterocycloalkyl group is unsubstituted or substituted with 1 or 2 groups that are independently selected from alkyl, halogen, —NR 8 R 9 , and alkoxy;

J is —C(═NR 7 )NR 8 R 9 or —NH—C(═NR 7 )NR 8 R 9 wherein

R 7 is selected from H, CN, NO 2 , alkyl, alkanoyl, arylalkanoyl and —C(═O)NR 10 R 11 , wherein

R 10 and R 11 are independently selected from H, and alkyl, and

R 8 and R 9 are independently selected from H, alkyl, hydroxy, alkoxy, alkoxyalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups; or

R 8 and R 9 and the nitrogen to which they are attached form a 5, 6 or 7 membered heterocycloalkyl ring, which is unsubstituted or substituted with 1, 2, or 3 groups that are independently selected from alkyl, alkoxy, hydroxy, and halogen;

or

R 7 , R 8 , and the nitrogens to which they are attached form a 5, 6 or 7 membered heterocycloalkyl group that is unsubstituted or substituted with 1, 2 or 3 groups that are independently selected from alkyl, alkoxy, hydroxy, and halogen; and

R 9 is selected from H, alkyl, hydroxy, alkoxy, alkoxyalkyl, heterocycloalkylalkyl, arylalkyl, and heteroarylalkyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups;

R 4 is selected from H, alkyl, and arylalkyl, wherein the arylalkyl group is unsubstituted or substituted with 1, 2, 3, 4, or 5 R 6 groups; and

R 5 is —M—G—A, wherein

M is aryl, wherein M is unsubstituted or substituted with 1, 2, 3, or 4 groups that are independently selected from halogen, alkyl, hydroxy, alkoxy, haloalkyl, —CN, haloalkoxy, and hydroxyalkyl;

G is selected from a direct bond between M and A, CH 2 , -alkyl-O—, —O-alkyl-, O, S, SO, and SO 2 ;

A is aryl, wherein A is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently selected from halogen, alkyl, alkoxy, haloalkyl, aryloxy, heteroaryloxy, arylalkoxy, heteroarylalkoxy, haloalkoxy, —CN, and NO 2 ;

with the proviso that when M is phenyl, G is a direct bond between M and A, and A is phenyl, then at least one of the four remaining hydrogens on the phenyl ring of M, of M—G—A, must be substituted with a group independently selected from halogen, alkyl, hydroxy, alkoxy, haloalkyl, —CN, haloalkoxy, and hydroxyalkyl.

2. The compound according to claim 1 , wherein

R 1 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, phenyl C 1 -C 6 alkyl, and phenyl C 1 -C 6 alkanoyl, wherein the phenylalkyl and phenylalkanoyl groups are unsubstituted or substituted with 1, 2, 3, 4, or 5 R 6 groups, and

R 2 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 1 -C 6 alkanoyl, phenyl C 1 -C 6 alkyl and phenyl C 1 -C 6 alkanoyl, wherein the phenylalkyl and phenylalkanoyl groups are unsubstituted or substituted with 1, 2, 3, 4, or 5 R 6 groups,

wherein R 6 at each occurrence is independently selected from the group consisting of halogen, hydroxy, —NO 2 , —CN, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, CF 3 , and OCF 3 .

3. The compound according to claim 1 , wherein

R 3 is —Z—Q—J, wherein

Z is a C 1 -C 6 alkyl, C 1 -C 6 alkoxy C 1 -C 6 alkyl, or C 1 -C 6 alkylthio C 1 -C 6 alkyl, each of which is unsubstituted or substituted with 1 or 2 groups independently selected from C 1 -C 4 alkyl, halogen, and C 1 -C 4 alkoxy;

Q is a direct bond between Z and J, —C(═O)—, piperidinyl, pyrrolyl, piperazinyl, imidazolidinyl, morpholinyl, thiomorpholinyl, azepanyl, or azocanyl wherein

each is unsubstituted or substituted with 1 or 2 groups that are independently selected from C 1 -C 4 alkyl, halogen, and C 1 -C 4 alkoxy;

J is —C(═NR 7 )NR 8 R 9 or —NH—C(═NR 7 )NR 8 R 9 , wherein

R 7 is selected from the group consisting of H, —CN, —NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkanoyl, phenyl C 1 -C 6 alkanoyl and —C(═O)NR 10 R 11 , wherein

R 10 and R 11 are independently selected from H and C 1 -C 6 alkyl,

R 8 and R 9 are each independently selected from the group consisting of H, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, alkoxy C 1 -C 6 alkyl, morpholinyl C 1 -C 6 alkyl, thiomorpholinyl, thiomorpholinyl S,S-dioxide, thiomorpholinyl S-oxide, piperidinyl C 1 -C 6 alkyl, pyrrolidinyl C 1 -C 6 alkyl, imidazolidinyl C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, phenyl C 1 -C 6 alkyl, and pyridyl C 1 -C 6 alkyl, pyridazyl C 1 -C 6 alkyl, pyrimidyl C 1 -C 6 alkyl, pyrazinyl C 1 -C 6 alkyl, thienyl C 1 -C 6 alkyl, and furyl C 1 -C 6 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups; or

R 8 and R 9 and the nitrogen to which they are attached form a 5, 6 or 7 membered heterocycloalkyl ring, which is unsubstituted or substituted with 1, 2, or 3 groups that are independently selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, and halogen; or

R 7 , R 8 , and the nitrogens to which they are attached form a 5, 6 or 7 membered heterocycloalkyl group that is unsubstituted or substituted with 1, 2 or 3 groups that are independently selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, and halogen; and

R 9 is selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkoxy C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, and C 1 -C 6 alkyl substituted with at least one of morpholinyl, piperidinyl, thiomorpholinyl, thiomorpholinyl S-oxide, phenyl, naphthyl, thiomorpholinyl S,S-dioxide, pyrrolidinyl, pyridyl, pyridazyl, pyrimidyl, pyrazinyl, and imidazolyl,

wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups, wherein

R 6 at each occurrence is independently selected from the group consisting of halogen, hydroxy, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, CF 3 , and OCF 3 .

4. The compound according to claim 1 , wherein

R 5 is —M—G—A, wherein

M is phenyl, wherein M is unsubstituted or substituted with 1, 2, 3, or 4 groups that are independently selected from the group consisting of halogen, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, halo C 1 -C 6 alkyl, halo C 1 -C 6 alkoxy, and hydroxy C 1 -C 6 alkyl,

G is selected from a direct bond between M and A, CH 2 , O, S, SO, and SO 2 ;

A is selected from the group consisting of phenyl, naphthyl, tetrahydronaphthyl, and dihydronaphthyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently selected from halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo C 1 -C 6 alkyl, halo C 1 -C 6 alkoxy, CN, and NO 2 .

5. The compound according to claim 1 , wherein

R 1 is hydrogen, C 1 -C 6 alkyl or benzyl;

R 2 is hydrogen, C 1 -C 6 alkyl or benzyl; and

R 3 is —Z—Q—J, wherein

Z is C 1 -C 6 alkyl, C 1 -C 6 alkoxy C 1 -C 6 alkyl, or C 1 -C 6 alkylthio C 1 -C 6 alkyl, each of which is unsubstituted or substituted with 1 or 2 C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy;

Q is a direct bond between Z and J, —C(═O)—, piperidinyl, pyrrolyl, piperazinyl, imidazolidinyl, morpholinyl, thiomorpholinyl, azepanyl, or azocanyl wherein each of the above is unsubstituted or substituted with 1 or 2 groups that are independently C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy;

J is —C(═NR 7 )NR 8 R 9 or —NH—C(═NR 7 )NR 8 R 9 , wherein

R 7 is selected from the group consisting of H, —CN, —NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkanoyl, phenyl C 1 -C 6 alkanoyl and —C(═O)NR 10 R 11 , wherein

R 10 and R 11 are independently H, or C 1 -C 6 alkyl, and

R 8 and R 9 are independently selected from the group consisting of H, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, alkoxy C 1 -C 6 alkyl, morpholinyl C 1 -C 6 alkyl, thiomorpholinyl, thiomorpholinyl S,S-dioxide, thiomorpholinyl S-oxide, piperidinyl C 1 -C 6 alkyl, pyrrolidinyl C 1 -C 6 alkyl, imidazolidinyl C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, phenyl C 1 -C 6 alkyl, and pyridyl C 1 -C 6 alkyl, pyridazyl C 1 -C 6 alkyl, pyrimidyl C 1 -C 6 alkyl, pyrazinyl C 1 -C 6 alkyl, thienyl C 1 -C 6 alkyl, and furyl C 1 -C 6 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups; or

R 8 and R 9 and the nitrogen to which they are attached form a 5, 6 or 7 membered heterocycloalkyl ring, which is unsubstituted or substituted with 1, 2, or 3 groups that are independently selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, and halogen; or

R 7 , R 8 , and the nitrogens to which they are attached form a 5, 6, or 7 membered heterocycloalkyl group that is unsubstituted or substituted with 1, 2 or 3 groups that are independently selected from C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, and halogen, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups, wherein R 6 at each occurrence is independently selected from the group consisting of halogen, hydroxy, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, CF 3 , and OCF 3 ; and

R 9 is selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkoxy C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, and C 1 -C 6 alkyl substituted with at least one of morpholinyl, piperidinyl, thiomorpholinyl, thiomorpholinyl S-oxide, phenyl, naphthyl, thiomorpholinyl S,S-dioxide, pyrrolidinyl, pyridyl, pyridazyl, pyrimidyl, pyrazinyl, and imidazolyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups;

R 4 is selected from the group consisting of H, C 1 -C 4 alkyl, benzyl and phenethyl, wherein the benzyl and phenethyl groups are unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups;

R 5 is —M—G—A, wherein

M is phenyl, wherein M is unsubstituted or substituted with 1, 2, 3, or 4 groups that are independently selected from the group consisting of halogen, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, halo C 1 -C 6 alkyl, halo C 1 -C 6 alkoxy, and hydroxy C 1 -C 6 alkyl,

G is selected from a direct bond between M and A, CH 2 , O, S, SO, and SO 2 ;

A is selected from the group consisting of phenyl, naphthyl, tetrahydronaphthyl, and dihydronaphthyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, 4, or 5 groups that are independently halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, halo C 1 -C 6 alkyl, halo C 1 -C 6 alkoxy, CN, or NO 2 .

6. The compound according to claim 5 , wherein

R 5 is —M—G—A, wherein

M is phenyl, which is unsubstituted or substituted with 1, 2, or 3 groups that are independently selected from the group consisting of F, Cl, Br, C 1 -C 4 alkyl, hydroxy, methoxy, ethoxy, isopropoxy, CF 3 , OCF 3 , halo C 1 -C 4 alkyl, halo C 1 -C 4 alkoxy, and hydroxy C 1 -C 4 alkyl;

G is selected from a direct bond between M and A, CH 2 , O, S, SO, and SO 2 ;

A is selected from the group consisting of phenyl, naphthyl, tetrahydronaphthyl, and dihydronaphthyl, wherein each is unsubstituted or substituted with 1, 2, or 3 groups that are independently selected from the group consisting of F, Cl, Br, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo C 1 -C 4 alkyl, CF 3 , OCF 3 , —CN, and —NO 2 .

7. The compound according to claim 6 , wherein

R 3 is —Z—Q—J, wherein

Z is a C 1 -C 6 alkyl, C 1 -C 6 alkoxy C 1 -C 6 alkyl, or C 1 -C 6 alkylthio C 1 -C 6 alkyl, each of which is unsubstituted or substituted with 1 or 2 C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy groups;

Q is a direct bond between Z and J, —C(═O)—, piperidinyl, pyrrolyl, piperazinyl, imidazolidinyl, morpholinyl, or thiomorpholinyl, wherein each is unsubstituted or substituted with 1 or 2 groups that are independently C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy;

J is —C(═NR 7 )NR 8 R 9 or —NH—C(═NR 7 )NR 8 R 9 , wherein

R 7 is selected from the group consisting of H, CN, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkanoyl, and —C(═O)NR 10 R 11 , wherein

R 10 and R 11 are independently H, or C 1 -C 6 alkyl, and

R 8 and R 9 are independently selected from the group consisting of H, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, alkoxy C 1 -C 6 alkyl, morpholinyl C 1 -C 6 alkyl, thiomorpholinyl, C 3 -C 8 cycloalkyl, and C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups; wherein

R 6 at each occurrence is independently selected from the group consisting of halogen, hydroxy, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, CF 3 , and OCF 3 ; or

R 8 and R 9 and the nitrogen to which they are attached form a 5 or 6 membered heterocycloalkyl ring, which is unsubstituted or substituted with 1, 2, or 3 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, or halogen.

8. The compound according to claim 7 , wherein

R 3 is —Z—Q—J, wherein

Z is a C 1 -C 6 alkyl, C 1 -C 6 alkoxy C 1 -C 6 alkyl, or C 1 -C 6 alkylthio C 1 -C 6 alkyl, each of which is unsubstituted or substituted with 1 or 2 C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy groups;

Q is piperidinyl, pyrrolyl, piperazinyl, imidazolidinyl, morpholinyl, or thiomorpholinyl, wherein each is unsubstituted or substituted with 1 or 2 groups that are independently C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy; and

J is —C(═NR 7 )NR 8 R 9 , wherein

R 7 is selected from the group consisting of H, CN, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkanoyl, and —C(═O)NR 10 R 11 , wherein

R 10 and R 11 are independently H, or C 1 -C 6 alkyl, and

R 8 and R 9 are independently selected from the group consisting of H, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, alkoxy C 1 -C 6 alkyl, morpholinyl C 1 -C 6 alkyl, thiomorpholinyl, C 3 -C 8 cycloalkyl, and C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups, wherein R 6 at each occurrence is independently selected from the group consisting of halogen, hydroxy, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, CF 3 , and OCF 3 ; or

R 8 and R 9 and the nitrogen to which they are attached form a 5 or 6 membered heterocycloalkyl ring, which is unsubstituted or substituted with 1, 2, or 3 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, or halogen.

9. The compound according to claim 7 , wherein

R 8 and R 9 and the nitrogen to which they are attached form a morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl or pyrrolidinyl ring, each of which is unsubstituted or substituted with 1, 2, or 3 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, or halogen.

10. The compound according to claim 6 , wherein

R 3 is —Z—Q—J wherein

Z is a C 1 -C 6 alkyl, C 1 -C 6 alkoxy C 1 -C 6 alkyl, or C 1 -C 6 alkylthio C 1 -C 6 alkyl, each of which is unsubstituted or substituted with 1 or 2 C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy groups;

Q is a direct bond between Z and J, —C(═O)—, piperidinyl, pyrrolyl, piperazinyl, imidazolidinyl, morpholinyl, or thiomorpholinyl, wherein each is unsubstituted or substituted with 1 or 2 groups that are independently C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy;

J is —C(═NR 7 )NR 8 R 9 or —NH—C(═NR 7 )NR 8 R 9 , wherein

R 7 , R 8 , and the nitrogens to which they are attached form a 5, 6, or 7 membered heterocycloalkyl group that is unsubstituted or substituted with 1, or 2 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, or halogen; and

R 9 is selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkoxy C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, and C 1 -C 6 alkyl substituted with at least one of morpholinyl, piperidinyl, thiomorpholinyl, phenyl, naphthyl, pyrrolidinyl, pyridyl, pyridazyl, and imidazolyl, wherein each of the above is unsubstituted or substituted with 1, or 2 R 6 groups; wherein

R 6 at each occurrence is independently selected from the group consisting of halogen, hydroxy, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, CF 3 , and OCF 3 .

11. The compound according to claim 6 , wherein

R 3 is —Z—Q—J wherein

Z is a C 1 -C 6 alkyl, C 1 -C 6 alkoxy C 1 -C 6 alkyl, or C 1 -C 6 alkylthio C 1 -C 6 alkyl, each of which is unsubstituted or substituted with 1 or 2 C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy groups;

Q is piperidinyl, pyrrolyl, piperazinyl, imidazolidinyl, morpholinyl, or thiomorpholinyl, wherein each is unsubstituted or substituted with 1 or 2 groups that are independently C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy; and

J is —C(═NR 7 )NR 8 R 9 or —NH—C(═NR 7 )NR 8 R 9 , wherein

R 7 is selected from the group consisting of H, CN, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkanoyl, and —C(═O)NR 10 R 11 , wherein

R 10 and R 11 are independently H, or C 1 -C 6 alkyl, and

R 8 and R 9 are independently selected from the group consisting of H, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, alkoxy C 1 -C 6 alkyl, morpholinyl C 1 -C 6 alkyl, thiomorpholinyl, C 3 -C 8 cycloalkyl, and C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups; wherein

R 6 at each occurrence is independently selected from the group consisting of halogen, hydroxy, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, CF 3 , and OCF 3 .

12. The compound as in claim 1 of structural formula II

wherein R 3 , R 4 , and R 5 are as defined in claim 1 .

13. The compound according to claim 12 , wherein

R 4 is selected from the group consisting of H, C 1 -C 4 alkyl, and benzyl wherein the benzyl group is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups, wherein

R 6 at each occurrence is independently selected from the group consisting of halogen, hydroxy, —NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, CF 3 , and OCF 3 .

14. The compound according to claim 13 , wherein

R 5 is —M—G—A, wherein

M is phenyl, which is unsubstituted or substituted with 1, 2, or 3 groups that are independently selected from the group consisting of F, Cl, Br, C 1 -C 4 alkyl, hydroxy, methoxy, ethoxy, isopropoxy, CF 3 , OCF 3 , halo C 1 -C 4 alkyl, halo C 1 -C 4 alkoxy, and hydroxy C 1 -C 4 alkyl;

G is selected from a direct bond between M and A, CH 2 , O, S, SO, and SO 2 ;

A is selected from the group consisting of phenyl, naphthyl, tetrahydronaphthyl, and dihydronaphthyl, wherein each is unsubstituted or substituted with 1, 2, or 3 groups that are independently selected from the group consisting of F, Cl, Br, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo C 1 -C 4 alkyl, CF 3 , OCF 3 , CN, and NO 2 .

15. The compound according to claim 13 , wherein

R 3 is —Z—Q—J, wherein

Z is a C 1 -C 6 alkyl, C 1 -C 6 alkoxy C 1 -C 6 alkyl, or C 1 -C 6 alkylthio C 1 -C 6 alkyl, each of which is unsubstituted or substituted with 1 or 2 C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy groups;

Q is a direct bond between Z and J, —C(═O)—, piperidinyl, pyrrolyl, piperazinyl, imidazolidinyl, morpholinyl, thiomorpholinyl, azepanyl, or azocanyl wherein each is unsubstituted or substituted with 1 or 2 groups that are independently C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy;

J is —C(═NR 7 )NR 8 R 9 or —NH—C(═NR 7 )NR 8 R 9 , wherein

R 7 is selected from the group consisting of H, CN, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkanoyl, phenyl C 1 -C 6 alkanoyl and —C(═O)NR 10 R 11 , wherein

R 10 and R 11 are independently H, or C 1 -C 6 alkyl,

R 8 and R 9 are independently selected from the group consisting of H, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, alkoxy C 1 -C 6 alkyl, morpholinyl C 1 -C 6 alkyl, thiomorpholinyl, thiomorpholinyl S,S-dioxide, thiomorpholinyl S-oxide, piperidinyl C 1 -C 6 alkyl, pyrrolidinyl C 1 -C 6 alkyl, imidazolidinyl C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, phenyl C 1 -C 6 alkyl, and pyridyl C 1 -C 6 alkyl, pyridazyl C 1 -C 6 alkyl, pyrimidyl C 1 -C 6 alkyl, pyrazinyl C 1 -C 6 alkyl, thienyl C 1 -C 6 alkyl, and furyl C 1 -C 6 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups; or

R 8 and R 9 and the nitrogen to which they are attached form a 5, 6 or 7 membered heterocycloalkyl ring, which is unsubstituted or substituted with 1, 2, or 3 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, or halogen; or

R 7 , R 8 , and the nitrogens to which they are attached form a 5, 6, or 7 membered heterocycloalkyl group that is unsubstituted or substituted with 1, 2 or 3 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, or halogen, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups; wherein

R 6 at each occurrence is independently selected from the group consisting of halogen, hydroxy, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, CF 3 , and OCF 3 .

16. The compound according to claim 12 , of structural formula III

wherein

R 3 is —Z—Q—J, wherein

Z is a C 1 -C 6 alkyl, C 1 -C 6 alkoxy C 1 -C 6 alkyl, or C 1 -C 6 alkylthio C 1 -C 6 alkyl, each of which is unsubstituted or substituted with 1 or 2 C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy groups;

Q is a direct bond between Z and J, —C(═O)—, piperidinyl, pyrrolyl, piperazinyl, imidazolidinyl, morpholinyl, thiomorpholinyl, azepanyl, or azocanyl wherein

each is unsubstituted or substituted with 1 or 2 groups that are independently C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy;

J is —C(═NR 7 )NR 8 R 9 or —NH—C(═NR 7 )NR 8 R 9 , wherein

R 7 is selected from the group consisting of H, CN, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkanoyl, phenyl C 1 -C 6 alkanoyl and —C(═O)NR 10 R 11 , wherein

R 10 and R 11 are independently H, or C 1 -C 6 alkyl,

R 8 and R 9 are independently selected from the group consisting of H, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, alkoxy C 1 -C 6 alkyl, morpholinyl C 1 -C 6 alkyl, thiomorpholinyl, thiomorpholinyl S,S-dioxide, thiomorpholinyl S-oxide, piperidinyl C 1 -C 6 alkyl, pyrrolidinyl C 1 -C 6 alkyl, imidazolidinyl C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, phenyl C 1 -C 6 alkyl, and pyridyl C 1 -C 6 alkyl, pyridazyl C 1 -C 6 alkyl, pyrimidyl C 1 -C 6 alkyl, pyrazinyl C 1 -C 6 alkyl, thienyl C 1 -C 6 alkyl, and furyl C 1 -C 6 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups; or

R 8 and R 9 and the nitrogen to which they are attached form a 5, 6 or 7 membered heterocycloalkyl ring, which is unsubstituted or substituted with 1, 2, or 3 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, or halogen; or

R 7 , R 8 , and the nitrogens to which they are attached form a 5, 6, or 7 membered heterocycloalkyl group that is unsubstituted or substituted with 1, 2 or 3 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, or halogen; wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups; wherein

R 6 at each occurrence is independently selected from the group consisting of halogen, hydroxy, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, CF 3 , and OCF 3 ; and

R 5 is —M—G—A, wherein

M is phenyl, which is unsubstituted or substituted with 1, 2, or 3 groups that are independently selected from the group consisting of F, Cl, Br, C 1 -C 4 alkyl, hydroxy, methoxy, ethoxy, isopropoxy, CF 3 , OCF 3 , halo C 1 -C 4 alkyl, halo C 1 -C 4 alkoxy, and hydroxy C 1 -C 4 alkyl;

G is selected from a direct bond between M and A, CH 2 , O, S, SO, and SO 2 ; and

A is selected from the group consisting of phenyl, naphthyl, tetrahydronaphthyl, and dihydronaphthyl, wherein each is unsubstituted or substituted with 1, 2, or 3 groups that are independently selected from the group consisting of F, Cl, Br, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo C 1 -C 4 alkyl, CF 3 , OCF 3 , CN, and NO 2 .

17. The compound according to claim 16 , wherein

R 3 is —Z—Q—J, wherein

Z is a C 1 -C 6 alkyl, C 1 -C 6 alkoxy C 1 -C 6 alkyl, or C 1 -C 6 alkylthio C 1 -C 6 alkyl, each of which is unsubstituted or substituted with 1 or 2 C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy groups;

Q is a direct bond between Z and J, —C(═O)—, piperidinyl, pyrrolyl, piperazinyl, imidazolidinyl, morpholinyl, or thiomorpholinyl, wherein

each is unsubstituted or substituted with 1 or 2 groups that are independently C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy;

J is —C(═NR 7 )NR 8 R 9 or —NH—C(═NR 7 )NR 8 R 9 , wherein

R 7 is selected from the group consisting of H, CN, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkanoyl, and —C(═O)NR 10 R 11 , wherein

R 10 and R 11 are independently H, or C 1 -C 6 alkyl,

R 8 and R 9 are independently selected from the group consisting of H, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, alkoxy C 1 -C 6 alkyl, morpholinyl C 1 -C 6 alkyl, piperidinyl C 1 -C 6 alkyl, pyrrolidinyl C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, benzyl, phenethyl, and pyridyl C 1 -C 6 alkyl, pyridazyl C 1 -C 6 alkyl, and furyl C 1 -C 6 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups; or

R 8 and R 9 and the nitrogen to which they are attached form a 5, 6 or 7 membered heterocycloalkyl ring, which is unsubstituted or substituted with 1, 2, or 3 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, or halogen; or

R 7 , R 8 , and the nitrogens to which they are attached form a 5, 6, or 7 membered heterocycloalkyl group that is unsubstituted or substituted with 1, 2 or 3 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, or halogen; wherein

R 6 at each occurrence is independently selected from the group consisting of halogen, hydroxy, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, CF 3 , and OCF 3 ; and

R 5 is —M—G—A, wherein

M is phenyl, which is unsubstituted or substituted with 1, 2, or 3 groups that are independently selected from the group consisting of F, Cl, Br, C 1 -C 4 alkyl, hydroxy, methoxy, ethoxy, isopropoxy, CF 3 , OCF 3 , halo C 1 -C 4 alkyl, halo C 1 -C 4 alkoxy, and hydroxy C 1 -C 4 alkyl;

G is selected from a direct bond between M and A, CH 2 , and O; and

A is selected from the group consisting of phenyl, naphthyl, tetrahydronaphthyl, and dihydronaphthyl, wherein each is unsubstituted or substituted with 1, 2, or 3 groups that are independently selected from the group consisting of F, Cl, Br, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo C 1 -C 4 alkyl, CF 3 , OCF 3 , CN, and NO 2 .

18. The compound according to claim 17 , of structural formula IV

wherein

R 3 is defined in claim 17 , and

X is CH or CR 11 ;

R 12 and R 13 are at each occurrence are independently selected from the group consisting of H, halogen, CF 3 , C 1 -C 4 alkyl, and C 1 -C 4 alkoxy;

A is selected from the group consisting of phenyl, naphthyl, and tetrahydronaphthyl, wherein each is unsubstituted or substituted with 1, 2, or 3 groups that are independently selected from the group consisting of F, Cl, Br, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo C 1 -C 4 alkyl, CF 3 , OCF 3 , CN, and NO 2 ; and

G is selected from a direct bond between M and A, CH 2 , and O.

19. The compound according to claim 18 , of structural formula V

wherein

R 3 , is as defined in claim 18 ,

A is phenyl, 3-fluorophenyl, 4-fluorophenyl, 4-chlorophenyl, 4-cyanophenyl, benzo[1,3]dioxyl, 3,5-dimethylphenyl, 2-naphthyl, or 2-tetrahydronaphthyl;

G is a direct bond between M and A, or G is oxygen; and

R 12 and R 13 are independently H, fluoro, chloro, CF 3 , methyl or methoxy.

20. The compound according to claim 19 , wherein

R 3 is —Z—Q—J, wherein

Z is a C 1 -C 6 alkyl, C 1 -C 6 alkoxy C 1 -C 6 alkyl, or C 1 -C 6 alkylthio C 1 -C 6 alkyl, each of which is unsubstituted or substituted with 1 or 2 C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy groups;

Q is a direct bond between Z and J or —C(═O)—,

J is —NH—C(═NR 7 )NR 8 R 9 , wherein

R 7 is selected from the group consisting of H, CN, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkanoyl, and —C(═O)NR 10 R 11 , wherein

R 10 and R 11 are independently H, or C 1 -C 6 alkyl, and

R 8 and R 9 are independently selected from the group consisting of H, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, alkoxy C 1 -C 6 alkyl, morpholinyl C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, and C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups, wherein

R 6 at each occurrence is independently selected from the group consisting of halogen, hydroxy, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, CF 3 , and OCF 3 , or

R 8 and R 9 and the nitrogen to which they are attached form a 5, 6 or 7 membered heterocycloalkyl ring, which is unsubstituted or substituted with 1, 2, or 3 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, or halogen.

21. The compound according to claim 19 , wherein

R 3 is —Z—Q—J, wherein

Z is a C 1 -C 6 alkyl, C 1 -C 6 alkoxy C 1 -C 6 alkyl, or C 1 -C 6 alkylthio C 1 -C 6 alkyl, each of which is unsubstituted or substituted with 1 or 2 C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy groups;

Q is a direct bond between Z and J or —C(O)—,

J is —NH—C(═NR 7 )NR 8 R 9 , wherein

R 7 , R 8 , and the nitrogens to which they are attached form a 5, 6, or 7 membered heterocycloalkyl group that is unsubstituted or substituted with 1, 2 or 3 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, or halogen; and

R 9 is selected from the group consisting of H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkoxy C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, and C 1 -C 6 alkyl substituted with at least one of morpholinyl, piperidinyl, thiomorpholinyl, phenyl, naphthyl, pyrrolidinyl, pyridyl, pyridazyl, pyrimidyl, pyrazinyl, and imidazolyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups, wherein

R 6 at each occurrence is independently selected from the group consisting of halogen, hydroxy, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, CF 3 , and OCF 3 .

22. The compound according to claim 19 , wherein

R 3 is —Z—Q—J, wherein

Z is a C 1 -C 6 alkyl, C 1 -C 6 alkoxy C 1 -C 6 alkyl, or C 1 -C 6 alkylthio C 1 -C 6 alkyl, each of which is unsubstituted or substituted with 1 or 2 C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy groups;

Q is a direct bond between Z and J, piperidinyl, pyrrolyl, piperazinyl, imidazolidinyl, morpholinyl, or thiomorpholinyl, wherein

each is unsubstituted or substituted with 1 or 2 groups that are independently C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy;

J is —C(═NR 7 )NR 8 R 9 wherein

R 7 is selected from the group consisting of H, CN, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkanoyl, and —C(═O)NR 10 R 11 , wherein

R 10 and R 11 are independently H, or C 1 -C 6 alkyl,

R 8 and R 9 are independently selected from the group consisting of H, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, alkoxy C 1 -C 6 alkyl, morpholinyl C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, and C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups; or

R 8 and R 9 and the nitrogen to which they are attached form a 5, 6 or 7 membered heterocycloalkyl ring, which is unsubstituted or substituted with 1, 2, or 3 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, or halogen; wherein

R 6 at each occurrence is independently selected from the group consisting of halogen, hydroxy, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, CF 3 , and OCF 3 .

23. The compound of structural formula VII

wherein

R 3 is —Z—Q—J, wherein

Z is a C 1 -C 10 alkyl, C 1 -C 6 alkoxy C 1 -C 6 alkyl, or C 1 -C 6 alkylthio C 1 -C 6 alkyl, each of which is unsubstituted or substituted with 1 or 2 C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy groups;

Q is a direct bond between Z and J, —C(═O)—, piperidinyl, pyrrolyl, piperazinyl, imidazolidinyl, morpholinyl, thiomorpholinyl, azepanyl, or azocanyl wherein

each is unsubstituted or substituted with 1 or 2 groups that are independently C 1 -C 4 alkyl, halogen, or C 1 -C 4 alkoxy;

J is —NH—C(═NR 7 )NR 8 R 9 , wherein

R 7 is selected from the group consisting of H, CN, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkanoyl, phenyl C 1 -C 6 alkanoyl and —C(═O)NR 10 R 11 , wherein

R 10 and R 11 are independently H, or C 1 -C 6 alkyl,

R 8 and R 9 are independently selected from the group consisting of H, C 1 -C 6 alkyl, hydroxy, C 1 -C 6 alkoxy, alkoxy C 1 -C 6 alkyl, morpholinyl C 1 -C 6 alkyl, thiomorpholinyl, thiomorpholinyl S,S-dioxide, thiomorpholinyl S-oxide, piperidinyl C 1 -C 6 alkyl, pyrrolidinyl C 1 -C 6 alkyl, imidazolidinyl C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, phenyl C 1 -C 6 alkyl, and pyridyl C 1 -C 6 alkyl, pyridazyl C 1 -C 6 alkyl, pyrimidyl C 1 -C 6 alkyl, pyrazinyl C 1 -C 6 alkyl, thienyl C 1 -C 6 alkyl, and furyl C 1 -C 6 alkyl, wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups; or

R 8 and R 9 and the nitrogen to which they are attached form a 5, 6 or 7 membered heterocycloalkyl ring, which is unsubstituted or substituted with 1, 2, or 3 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, or halogen; or

R 7 , R 8 , and the nitrogens to which they are attached form a 5, 6, or 7 membered heterocycloalkyl group that is unsubstituted or substituted with 1, 2 or 3 groups that are independently C 1 -C 6 alkyl, C 1 -C 6 alkoxy, hydroxy, or halogen; wherein each of the above is unsubstituted or substituted with 1, 2, 3, or 4 R 6 groups; wherein

R 6 at each occurrence is independently selected from the group consisting of halogen, hydroxy, NO 2 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, CF 3 , and OCF 3 ; and

R 5 is —M—G—A, wherein

M is phenyl, which is substituted with 1, 2, or 3 groups that are independently selected from the group consisting of F, Cl, Br, C 1 -C 4 alkyl, hydroxy, methoxy, ethoxy, isopropoxy, CF 3 , OCF 3 , halo C 1 -C 4 alkyl, halo C 1 -C 4 alkoxy, and hydroxy C 1 -C 4 alkyl;

G is selected from a direct bond between M and A, and O; and

A is selected from the group consisting of phenyl, naphthyl, tetrahydronaphthyl, and dihydronaphthyl, wherein each is unsubstituted or substituted with 1, 2, or 3 groups that are independently selected from the group consisting of F, Cl, Br, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, halo C 1 -C 4 alkyl, CF 3 , OCF 3 , CN, and NO 2 .

24. A compound or pharmaceutically acceptable salt thereof of structural formula VIII:

wherein R 3 is selected from:

and R 5 is selected from:

and

25. A compound or pharmaceutically acceptable salt thereof listed in the following table:

2

N 1 -hydroxy-N 2 -[(4-phenoxyphenyl)sulfonyl]-D-argininamide

3

N 2 -{[4-(4-fluorophenoxy)phenyl]sulfonyl}-N 1 -hydroxy-D-

argininamide

4

N 2 -[(3-fluoro-4-phenoxyphenyl)sulfonyl]-N 1 -hydroxy-D-

argininamide

5

N 2 -[(3,5-difluoro-4-phenoxyphenyl)sulfonyl]-N 1 -hydroxy-D-

argininamide

6

N 2 -{[4-(4-chlorophenoxy)-3,5-difluorophenyl]sulfonyl}-N 1 -

hydroxy-D-argininamide

7

N 2 -{[3,5-difluoro-4-(4-fluorophenoxy)phenyl]sulfonyl}-N 1 -

hydroxy-D-argininamide

8

N 2 -{[4-(4-bromophenoxy)-3,5-difluorophenyl]sulfonyl}-N 1 -

hydroxy-D-argininamide

9

N 2 -{[3-fluoro-4-(4-fluorophenoxy)phenyl]sulfonyl}-N 1 -hydroxy-

D-argininamide

10

N 2 -{[4-(4-chlorophenoxy)-3-fluorophenyl]sulfonyl}-N 1 -hydroxy-

D-argininamide

11

N 2 -{[4-(4-cyanophenoxy)-3-fluorophenyl]sulfonyl}-N 1 -hydroxy-

D-argininamide

12

N 2 -{[4-(3,5-dimethylphenoxy)-3-fluorophenyl]sulfonyl}-N 1 -

hydroxy-D-argininamide

14

N 1 -hydroxy-N 2 -{[6-(5,6,7,8-tetrahydronaphthalen-2-

yloxy)pyridin-3-yl]sulfonyl}-D-argininamide

16

N 5 -[(Z)-amino(nitroimino)methyl]-N 1 -hydroxy-N 2 -[(4-

phenoxyphenyl)sulfonyl]-D-ornithinamide

18

N 6 -[(E)-amino(cyanoimino)methyl]-N 1 -hydroxy-N 2 -[(4-

phenoxyphenyl)sulfonyl]-D-lysinamide

20

N 6 -{(Z)-(cyanoimino)[(2-methoxyethyl)amino]methyl}-N 1 -

hydroxy-N 2 -[(4-phenoxyphenyl) sulfonyl]-D-lysinamide

21

N 6 -{(Z)-(cyanoimino)[(2-methoxyethyl)amino]methyl}-N 2 -{[4-(4-

fluorophenoxy)phenyl] sulfonyl}-N 1 -hydroxy-D-lysinamide

23

N 6 -[(E)-(cyanoimino)(propylamino)methyl]-N 1 -hydroxy-N 2 -[(4-

phenoxyphenyl)sulfonyl]-D-lysinamide

24

N 6 -[(E)-(cyanoimino)(propylamino)methyl]-N 2 -{[4-(4-

fluorophenoxy)phenyl]sulfonyl}-N 1 -hydroxy-D-lysinamide

26

N 6 -{(Z)-(cyanoimino)[(2-morpholin-4-ylethyl)amino]methyl}-N 1 -

hydroxy-N 2 -[(4-phenoxyphenyl) sulfonyl]-D-lysinamide

27

N 6 -[(Z)-(cyanoimino)(cyclopropylamino)methyl]-N 1 -hydroxy-N 2 -

[(4-phenoxyphenyl) sulfonyl]-D-lysinamide

28

N 6 -[(E)-[(aminocarbonyl)imino](hydroxyamino)methyl]-N 2 -{[4-

(4-fluorophenoxy)phenyl] sulfonyl}-N 1 -hydroxy-D-lysinamide

37

N 6 -[(E)-(cyanoimino)(morpholin-4-yl)methyl]-N 2 -{[4-(4-

fluorophenoxy)phenyl]sulfonyl}-N 1 -hydroxy-D-lysinamide

38

N 6 -[(Z)-(cyanoimino)(morpholin-4-yl)methyl]-N 2 -{[3-fluoro-4-

(4-fluorophenoxy)phenyl] sulfonyl}-N 1 -hydroxy-D-lysinamide

39

3-{1-[amino(imino)methyl]piperidin-4-yl}-N 1 -hydroxy-N 2 -[(4-

phenoxyphenyl)sulfonyl]alaninamide

40

3-{1-[(Z)-(cyanoimino)(propylamino)methyl]piperidin-4-yl}-

N 1 -hydroxy-N 2 -[(4-phenoxyphenyl)sulfonyl]alaninamide

41

3-(1-{(Z)-(cyanoimino)[(2-

methoxyethyl)amino]methyl}piperidin-4-yl)-N 1 -hydroxy-N 2 -[(4-

phenoxyphenyl)sulfonyl]alaninamide

42

3-(1-{(E)-(cyanoimino)[(2-

methoxyethyl)amino]methyl}piperidin-4-yl)-N 2 -{[3,5-difluoro-

4-(4-fluorophenoxy)phenyl]sulfonyl}-N 1 -hydroxyalaninamide

43

3-(1-{(Z)-[(aminocarbonyl)imino][(2-

methoxyethyl)amino]methyl}piperidin-4-yl)-N 1 -hydroxy-N 2 -[(4-

phenoxyphenyl)sulfonyl]alaninamide

48

N 6 -4,5-dihydro-1H-imidazol-2-yl-N 2 -{[4-(4-

fluorophenoxy)phenyl]sulfonyl}-N 1 -hydroxy-D-lysinamide

55

N 1 -hydroxy-N 2 -{[4-(phenyloxy)phenyl]sulfonyl}-D-histidinamide

62

N 1 -hydroxy-N 2 -{[6-(naphthalen-1-yloxy)pyridin-3-yl]sulfonyl}-

D-argininamide

64

N 6 -[(E)-(cyanoimino)(hydroxyamino)methyl)]-N 2 -({4-[(4-

fluorophenyl)oxy]phenyl}sulfonyl)-N 1 -hydroxy-D-lysinamide

74

N 2 -({3,5-difluoro-4-[(4-hydroxyphenyl)oxy]phenyl}sulfonyl)-

N 1 -hydroxyargininamide

75

N 2 -{[3,5-difluoro-4-(pyridin-3-yloxy)phenyl]sulfonyl}-N 1 -

hydroxyargininamide

78

N 2 -{[3,5-difluoro-4-({4-

[(phenylmethyl)oxy]phenyl}oxy)phenyl]sulfonyl}-N 1 -

hydroxyargininamide

81

N 2 -({3,5-difluoro-4-[(4-fluorophenyl)oxy]phenyl}sulfonyl)-N 1 -

hydroxy-4-[(hydroxyamino)(imino)methyl]-D-phenylalaninamide

82

N 2 -({3,5-difluoro-4-[(4-fluorophenyl)oxy]phenyl}sulfonyl)-N 1 -

hydroxy-3-[(hydroxyamino)(imino)methyl]-D-phenylalaninamide

84

N 2 -({3,5-difluoro-4-[(4-fluorophenyl)oxy]phenyl}sulfonyl)-N 1 -

hydroxy-3-[1-(morpholin-4-ylcarbonyl)piperidin-4-

yl]alaninamide

85

3-[amino(imino)methyl]-N 2 -({3,5-difluoro-4-[(4-

fluorophenyl)oxy]phenyl}sulfonyl)-N 1 -hydroxy-D-

phenylalaninamide

86

4-[amino(imino)methyl]-N 2 -({3,5-difluoro-4-[(4-

fluorophenyl)oxy]phenyl}sulfonyl)-N 1 -hydroxy-D-

phenylalaninamide

92

(2R)-4-{[amino(imino)methyl]amino}-N 2 -[({4-[(4-

chlorophenyl)oxy]-3,5-difluorophenyl}sulfonyl)amino]-N 1 -

hydroxybutanamide.

26. A pharmaceutical composition comprising a compound according claim 1 and a pharmaceutically acceptable carrier.

27. A method of treating breast cancer, arthritis, and stroke comprising administering to a mammal in need of such treatment a therapeutically effective amount of a pharmaceutical composition according to claim 26 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2004
From: BROWN, S. DAVID; CANNE, LYNNE; CO, ERICK W.; JAMMALAMADAKA, VASU; KHOURY, RICHARD G.; KIM, MOON HWAN; LE, DONNA T.; LEW, AMY; MAC, MORRISON B.; MAMO, SHUMEYE; NUSS, JOHN M.; PRISBYLLA, MICHAEL P.; XU, WEI
To: EXELIXIS, INC.
Reel/Frame 014866/0822 →